Production (Stage)
CureVac N.V.
CVAC
$5.57
-$0.03-0.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -93.00% | 1,015.26% | 1,457.62% | 88.35% | 75.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -93.00% | 1,015.26% | 1,457.62% | 88.35% | 75.69% |
| Cost of Revenue | -97.97% | -74.70% | -51.71% | 55.75% | 104.53% |
| Gross Profit | 100.06% | 1,150.03% | 3,242.06% | -42.23% | -119.75% |
| SG&A Expenses | -15.94% | -34.30% | -4.96% | -29.24% | -15.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 92.52% | 51.74% | -3,456.77% | 103.24% | -1,504.94% |
| Total Operating Expenses | -37.08% | -24.96% | 6.34% | 6.16% | 25.11% |
| Operating Income | 27.64% | 331.57% | 429.59% | 2.46% | -19.31% |
| Income Before Tax | 28.35% | 290.05% | 444.48% | -4.54% | -23.21% |
| Income Tax Expenses | -37.55% | 7,921.17% | 225,932.31% | 4,848.06% | 65,627.27% |
| Earnings from Continuing Operations | 28.44% | 274.42% | 416.71% | -6.41% | -24.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.44% | 274.42% | 416.71% | -6.41% | -24.38% |
| EBIT | 27.64% | 331.57% | 429.59% | 2.46% | -19.31% |
| EBITDA | 28.98% | 346.91% | 472.25% | 1.82% | -22.96% |
| EPS Basic | 28.71% | 274.30% | 415.98% | -6.19% | -17.24% |
| Normalized Basic EPS | 28.62% | 341.00% | 472.01% | -0.24% | -- |
| EPS Diluted | 28.71% | 272.90% | 415.34% | -6.19% | -17.24% |
| Normalized Diluted EPS | 28.62% | 341.00% | 472.01% | -0.24% | -- |
| Average Basic Shares Outstanding | 0.36% | 0.07% | 0.24% | 0.19% | 6.10% |
| Average Diluted Shares Outstanding | 0.36% | 0.07% | 0.24% | 0.19% | 6.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |